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Available online 16 August 2018Therapies against hepatitis B virus (HBV) have improved in recent decades; however, the development of indi-
vidualized treatments has been limited by the lack of individualized infection models. In this study, we used
human induced pluripotent stem cell (hiPSC) to generate a functional liver organoid (LO) that inherited the ge-
netic background of the donor, and evaluated its application inmodeling HBV infection and exploring virus–host
interactions. To establish a functional hiPSC-LO, we cultured hiPSC-derived endodermal, mesenchymal, and en-
dothelial cellswith a chemically deﬁnedmedium in a three-dimensionalmicrowell culture system. Based on cell-
cell interactions, these cells could organize themselves and gradually differentiate into a functional organoid,
which exhibited stronger hepatic functions than hiPSC derived hepatic like cell (HLC). Moreover, the functional
LO demonstratedmore susceptibility to HBV infection than hiPSC-HLC, and couldmaintain HBV propagation and
produce infectious virus for a prolonged duration. Furthermore,we found that virus infection could cause hepatic
dysfunction of hiPSC-LOs, with down-regulation of hepatic gene expression, induced release of early acute liver
failure markers, and altered hepatic ultrastructure. Therefore, our study demonstrated that HBV infection in
hiPSC-LOs could recapitulate virus life cycle and virus induced hepatic dysfunction, suggesting that hiPSC-LOs
may provide a promising individualized infection model for the development of individualized treatment for
hepatitis.tive Med
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. This is©2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Virus-host interactions1. IntroductionAlthough vaccines and therapies against hepatitis B virus (HBV)
have improved in recent decades, an estimated 257 million people are
still livingwith hepatitis B virus infectionwithmarkedly heterogeneous
outcomes [1, 2]. Some individuals have self-limiting, symptom-free in-
fection, whereas others develop liver cirrhosis and/or hepatocellular
carcinoma [2]. This drastic heterogeneity in outcome cannot be justiﬁed
completely by the contributing factors, such as viral genotype diversity,
environmental and demographic variables, and differences in age of pa-
tient with infection [3]. Evidence has indicated that the genetic back-
ground of the host might play an important role in virus-inducedicine, Yokohama City
6-0004, Japan.
an open access article underoutcomes [4, 5]. Although various models have been developed for
HBV infection, these models do not represent individualized genetic
backgrounds, which limits their application in understanding the po-
tential impact of the host's genetic makeup during virus infection.
Since long, primary human hepatocytes (PHH) have been a valuable
model for HBV infection studies [6]; however, donor shortage and vari-
able quality limit their applications. More recently, the Na+-
taurocholate cotransporting polypeptide (NTCP) was identiﬁed as a
HBV entry receptor, and the exogenous expression of NTCP could suc-
cessfully induce susceptibility to HBV infection in non-susceptible
hepatocarcinoma cells [7]. However, the genetic background of these
hepatocarcinoma cells could not broadly represent the human popula-
tion. Hepatocytes from chimeric mice also face similar problems [8].
Therefore, the generation of new hepatocytes, with patient-speciﬁc ge-
netic background and susceptibility to HBV infection, is paramount for
individualized hepatitis studies.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cell (hiPSC) to differentiate into various terminal cell types, inheriting
the donor's genetic background, has been successfully tested and
proved [9]. This has created a unique opportunity to accurately model
diseases and develop new treatments by using hiPSCs. Studies have re-
ported that hiPSC-derived hepatic-like cells (hiPSC-HLC) could exhibit
and inherit hepatic characteristics similar to those of the donor [10,
11]. HBV infection have also been reported in hiPSC-HLC [12–14]. How-
ever, these HLCs displayed low hepatic function that was easily lost,
greatly limiting its application in the investigation of virus-host interac-
tions [12–15]. The liver is known to have a complex and highly orga-
nized architecture consisting of numerous cell types, with hepatic
differentiation being accurately controlled by its interactions with
non-parenchymal cells during liver organogenesis [16]. Therefore, re-
construction of these interactions might be a plausible approach to pro-
mote hepatic differentiation, long-term maintenance of hepatic
functions, and generation of an effective infection model to understand
virus-host interactions.
The liver develops from speciﬁc hepatic endoderm in a microenvi-
ronment surrounded by mesenchymal and endothelial progenitor
cells located in the septum transversum. The mesenchymal and endo-
thelial cell microenvironment has been considered a key element to ini-
tiate hepatic differentiation and promote liver development [17, 18]. By
recapitulating this microenvironment, we have previously generated a
self-organized hiPSC liver organoid (LO) that could grow into a
vascularized and functional tissue post-transplantation [19, 20]. How-
ever, the self-organized organoid had a few drawbacks such as limited
hepatic function before transplantation, and a huge size (approximate
diameter of 3000–5000 μm) that inhibited its ability to differentiate
well in vitro [19, 20]. In the current study, we aimed to generate a func-
tional hiPSC liver organoid that could act as a reliable and feasible ex vivo
infection model for hepatitis studies.2. Materials & methods
2.1. Cell culture
The TkDA3 human iPSC clone used in this studywas kindly provided
by K. Eto and H. Nakauchi. Undifferentiated iPSCsweremaintained on a
growth factor-reduced Matrigel (BD Biosciences, San Diego, CA)-coated
dish with mTeSR1 medium (Stem Cell Technologies, Vancouver, BC,
Canada). HUVECs and human bone marrow (BM)-MSCs were main-
tained in endothelial cell growth medium (Lonza, Walkersville, MD)
and mesenchymal cell growth medium (Lonza), respectively.
Cryopreserved PHHs (lot number: AKB (PHH-1) and TLY (PHH-2))
were puchased from Bioreclamation IVT (Baltimore, MD, USA) and
thawed according to the manufacturer's instruction. The PHHs were
cultured inWilliams E medium supplemented with 5% FBS, 1 μMDexa-
methasone, 100 IU/mL Penicillin, 100 μg/mL Streptomycin, 4 μg/mL
Human Recombinant Insulin, 2 mM GlutaMAXTM, and 15 mM HEPES
pH 7.4. 24 h later, PHHs were used for HBV infection, Q-PCR anaysis
and ELISA analysis.
Phoenix human hepatocytes (Phoenix-HHs) were isolated from hu-
manized mice (PhoenixBio Co., Ltd., Higashihiroshima, Japan), without
cryopreservation. Phoenix-HHswere cultured with hepatic growthme-
dium (PhoenixBio). After 24 h of culture, Phoenix-HHs were used for
HBV infection.
The HepG2-TET-NTCP cells were generated by Kei Miyakawa and
Akihide Ryo as previous report [21]. HepG2.2.15.7 cells were obtained
from Takaji Wakita [22], which are a HepG2.2.15 clone producing a
higher level of HBV. The HepG2-TET-NTCP cells and HepG2.2.15.7 cells
were maintained on collagen-I coated dishes with DMEM/F-12 (Life
Technologies, Gaithersburg, MD), 2 mM GlutaMAX (Life Technologies),
10% fetal bovine serum (Life Technologies), 10 mM HEPES (LifeTechnologies) and 5 μg/mL insulin (Sigma–Aldrich, St. Louis, MO). All
cells were maintained at 37 °C in a humidiﬁed incubator with 5% CO2.
2.2. Cell differentiation and organoid generation
To differentiate HLCs and LOs from hiPSC, we ﬁrst differentiated en-
doderm from hiPSC according to a previously reported protocol [23].
Then hiPSC-endoderm was then cultured and differentiated into HLC
as described previously [23].
To generate hiPSC-LOs, 2.5 × 105 hiPSC endoderm cells, 1.75 × 105
HUVECs, and 2.5 × 104 human BM-MSCs were co-cultured in a 3D
microwell plate (Elplasia, Kuraray, Tokyo, Japan) with a serum-free dif-
ferentiation (SFD) medium [24]. All cells were maintained at 37 °C in a
humidiﬁed incubator with 5% CO2. After 15 days of differentiation,
hiPSC-LOs were used for HBV infection experiments as well as other
analysis.
To generate HepG2-TET-NTCP organoids, 2.5 × 105 HepG2-TET-
NTCP cells, 1.75 × 105 HUVECs, and 2.5 × 104 human BM-MSCs were
co-cultured in DMEM/12: EGM= 1:1 with 1 mM GlutaMAX, 5% fetal
bovine serum, 5 mM HEPES and 2.5 μg/mL insulin in a 3D microwell
plate. After 24 h culture with or without DOX, HepG2-TET-NTCP
organoids were used for HBV infection experiments as well as other
analysis.
2.3. HBV preparation, infection and inhibition assays
HBV stocks were derived from supernatants of HepG2.2.15.7 cells,
which were stably transfected with a complete HBV genome (genotype
D) as described previously [21]. HiPSCs-LO, hiPSCs-HLC, HepG2-TET-
NTCP organoids, and PHHswere infectedwith HBV [500 genome equiv-
alents (GEq)/cell or 5000 GEq/cell] in the presence of 4% polyethylene
glycol 8000 in 24-well plates. After 10 days post infection or 20 days
post infection, cultured cells were then harvested. pg RNA was quanti-
ﬁed by SYBR Green (Takara Bio, Otsu, Japan) with primers listed in
Table S1. The expression of pg RNA was normalized against expression
of β-ACTB (Thermo Fisher Scientiﬁc, Waltham, MA).
In inhibition assay, hiPSC-LOs were infected with HBV at 5000 GEq/
cell, and 100 nMMyrcludex was added into the medium 2 h before in-
fection; 1.8 mM Entecavir was added to the medium during infection;
1000 IU/mL IFN-α (Sigma–Aldrich) and 1000 IU/mL IFN-γ (Sigma–Al-
drich) were added to the medium during infection.
2.4. Intracellular vDNA and cccDNA isolation and quantiﬁcation
Infected cells were collected after infection. Total DNA in the cells
were purifed using DNeasy Blood & Tissue Kit (QIAGEN, Hilden,
Germany). The concentration ofwere determined by naondrop spectro-
photometer (Thermo Fischer Scientiﬁc, Waltham, MA), and the DNA
concentration were adjust to 20 ng/μL for further experiment. 2 μL ad-
justed DNA sample were used to quatify vDNA by SYBR Green with a
standard curve done by using plasmid pUC-HBV over a range of 107–
101 copies. To quanty cccDNA copies, adjusted DNA sample 25 μL of
20 ng/μL of HBV DNA samples were treated with plasmid-safe DNase
at 37 °C for 1 h according to themanuscript. After digestion, the plasmid
safe DNase were inactivated at 70 °C for 30 min. 2 μL sample were used
to quantify cccDNA copies by SYBRGreenwith a standard curve done by
usingplasmid pUC-HBVover a range of 107–101 copies. The primer used
for HBV DNA and cccDNA quantiﬁcation were list in Table S1.
2.5. Supernatant vDNA isolation and quantiﬁcation
Supernatant from infected cells were collected. 200 μL supernatant
were mix with 200 μL AL buffere and 20 μL proteinase K. Total DNA in
the supernatant were then purifed using DNeasy Blood & Tissue Kit
(QIAGEN) and DNA was eluted with 30 μL of elusion buffer. 2 μL DNA
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standard curve done by using plasmid pUC-HBV over a range of 107–
101 copies. The primer used for HBV DNA quantiﬁcation were list in
Table S1.
2.6. RNA isolation and quantitative real-time polymerase chain reaction
Total RNA was isolated using a PureLink viral RNA/DNA mini kit
(Thermo Fisher Scientiﬁc, Carlsbad, CA). RNA (1 μg) was used as a tem-
plate for single-strand cDNA synthesis with a high-capacity cDNA re-
verse transcription kit (Thermo Fisher Scientiﬁc) according to the
manufacturer's instructions. Q-PCR was performed with cDNA using
speciﬁc primers and Universal Probe Library (UPL) probes. The primers
and UPL probes used in this study are listed in Table S1. All data were
calculated using the ΔΔCT method with β-ACTB (Thermo Fisher Scien-
tiﬁc) as a normalization control.
2.7. ALB assay, urea production, CYP3A, LDH release, and ALT assay
Human ALB was measured using a human ALB enzyme-linked im-
munosorbent assay kit (Bethyl Laboratories, Montgomery, TX). Urea
production was assayed using a QuantiChrom urea assay kit (BioAssay
System, Hayward, CA), CYP3A activity was detected using a P450-Glo
CYP3A4 assay kit (Promega, Madison, WI, USA), LDH release was de-
tected using the LDH Cytotoxicity Detection Kit (Roche, Roche,
Boehringer Mannheim, Germany), and ALT was detected using FUJI
DRI-CHEMSLIDEGPT/ALT-PIII (Tokyo, Japan) according to themanufac-
turer's instructions. The number of hiPSC-HLCs, and PHHs cells were an-
alyzed by Incell analyzer 2000 (GEHealthcare, Cardiff, UnitedKingdom)
with Hoechst 33342 staining. To calculate the cell number in LOs, total
DNA of the cell number counted hiPSC-HLCs and hiPSC-LOs were ex-
tracted using DNeasy Blood & Tissue Kit, and DNA were eluted with
50 μL of elusion buffer. Then the concentration of thoseDNAwere deter-
mined by naondrop spectrophotometer. The total cell number in hiPSC-
LOs were calculated by following formula:
hiPSC‐LOs cell number ¼ HLCs cell numberð Þ  LOs DNA amountð Þ
HLCs DNA amountð Þ
2.8. Indocyanine green uptake and release
ICG dry− powder (Akorn, Buffalo Grove, IL) (10 mg) was dissolved
in 10 mL of hepatocyte culture medium (HCM; Lonza) to obtain a 1
mg/mL stock. hiPSC-LOs were incubated with ICG in suspension or
plated for 4 h at 37 °C in a humidiﬁed incubator with 5% CO2. Then,
hiPSC-LOs were washed three times with phosphate-buffered saline
(PBS) and incubated in fresh HCM for another 5 h to determine the
ICG release.
2.9. Tissue processing and immunoﬂuorescence
hiPSC-LOs were embedded in optimal cutting temperature com-
pound (Sakura Finetek Japan., Co., Ltd., Tokyo, Japan), and 7-μmsections
were prepared and mounted on MAS-GP type A-coated slides
(Matsunami, Osaka, Japan). Sections were ﬁxed in a 4% paraformalde-
hyde solution in PBS for 10 min, washed three times with PBS, and
blocked for 60 minwith 10% ECL primeblocking agent in PBS containing
0.3% Triton X-100, followed by three washes with PBS. Then, the sec-
tions were incubated with HBc (Dako, Japan), HBs (Bio-rad, CA, USA),
ALB (Bethyl Laboratories) and NTCP antibodies in the blocking buffer
at 4 °C overnight. The sections were washed three times with PBS and
incubated with a ﬂuorescence-conjugated secondary antibody for an-
other 60 min at room temperature. Finally, the sections were washed
three times in PBS and covered with a mounting solution containing4′,6-diamidino-2-phenylindole. Fluorescence was detected with a
Zeiss Axio Imager M1 microscope. The NTCP antibody was produced
by Kei Miyakawa and Akihide Ryo and tested using HepG2-TET-NTCP
cells and organoids with or without doxycycline treatment (Fig. S2A
and S2B). The HBc antibody were tested in infected PHHs (Fig. S2D).
To quantiﬁcation of HBc positive cells, we ﬁrst count the ALB positive
cells according to ALB and nuclear staining, then count the HBc positive
cells among this ALB positive cells. The percentage of ALB+HBc+ in in-
fected hiPSC-LOs were calculated by following formula:
ALBþHBcþ percentage ¼ HBc
þ cell number in ALBþ cells
Total ALBþ cell number
 100%
2.10. Transmission electron microscopy
Samples in culture medium were ﬁxed with an equal amount of 4%
paraformaldehyde and 4% glutaraldehyde in 0.1 M phosphate buffer at
4 °C for 1 h, followed by incubation with 2% glutaraldehyde in 0.1 M
phosphate buffer at 4 °C overnight. The ﬁxed samples were postﬁxed
with 2% osmium tetroxide, dehydrated through a graded series of
ethyl alcohol, and embedded in a fresh 100% resin. Ultrathin sections
(70 nm) were cut with an ultramicrotome (Ultracut UCT, Leica, Vienna,
Austria) and stained with 2% uranyl acetate. Then, the sections were
washed with distilled water and stained with a lead stain solution.
Grids were observed under a transmission electron microscope (JEM-
1400Plus, JEOL, Ltd., Tokyo, Japan) at an acceleration voltage of 80 kV.
Digital images were taken with a CCD camera (VELETA, Olympus Soft
Imaging Solutions GmbH, Munster, Germany).
2.11. Statistics
Values are expressed as the mean ± standard error of the mean
(SEM). The statistical signiﬁcance of differences was evaluated by the
Mann-Whitney U test when two groups were compared or by one-
way ANOVA and Bonferroni's multiple comparison tests when multiple
groupswere compared. A p b .05was considered statistically signiﬁcant,
Statistical analysis was performed usingGraphPad Prism. Additional ex-
perimental procedures are listed in Supplemental informationMaterials
& Methods.
3. Results
3.1. In vitro generation of functional liver organoids from hiPSC
To generate functional liver organoids, we ﬁrst differentiated hiPSCs
into endoderm that expressed lineage speciﬁc hepatic makers (Fig. S1A
and S1B), and then co-cultured the hiPSC-endoderm with human um-
bilical vein endothelial cells (HUVECs) and mesenchymal stem cells
(MSCs) in a 3D microwell culture system (Fig. 1A). After 24 h, all three
co-cultured cells were found to self-organize into organoids having a
uniform size (205.1 ± 37.5 μm, n=532) (Fig. S1C). Quantitative poly-
merase chain reaction (Q-PCR) analysis was performed on hiPSC-LO
after 15 days of differentiation (Fig. 1B). The results revealed that
hiPSC-LO had differentiated into hepatic lineages with expression of
speciﬁc hepatic functional genes (Fig. 1C and Fig. S1D). We also found
that the expression of these genes in differentiated LOswas signiﬁcantly
higher than that in hiPSC-HLCs (Fig. 1C and Fig. S1D). In addition, the
omission of HUVECs and MSCs in hiPSC-LOs (hiPSC-LO w/o H/M)
could delay hepatic lineage differentiation with lower expression of he-
patic genes (Fig. 1C), indicating that the endothelial/mesenchymal envi-
ronment was important to promote hepatic differentiation in LOs.
Hepatic function analysis indicated that differentiated hiPSC-LOs
show about 4–8-fold higher ALB (albumin) secretion (Fig. 1D and
Fig. S1E), and 12-fold higher urea production than hiPSC-HLCs
Fig. 1. Generation of functional liver organoids from hiPSCs. (A) Schematic representation of generation and differentiation of liver organoids (LOs) from hiPSCs. After 15 days of
differentiation, differentiated LOs were collected and analyzed. (B) Morphology of hiPSC-LOs at day 1 and day 15. Scale bar, 100 μm. (C) Q-PCR analysis showing expression of hepatic
genes: ALB, G6PC, CYP2C9, CYP2C19, CYP3A4, and CYP3A7 in hiPSC-HLCs (n= 4), differentiated hiPSC-LOs w/o H/M (deletion of HUVEC and MSC at LOs generation) (n= 4), and
differentiated hiPSC-LOs (n=4). (D) ELISA for ALB secretion of hiPSC-HLCs (n= 9), differentiated hiPSC-LOs (n=11), PHH-1(24 h cultured, n= 3), and PHH-2 (24 h cultured, n=
3). (E) Quantiﬁcation of urea production in hiPSC-HLCs (n=8) and differentiated hiPSC-LOs (Day 15, n=8). (F) Quantiﬁcation of CYP3A activity in differentiated hiPSC-HLCs (n=4)
and hiPSC-LOs (n= 4), with or without 25 μM rifampicin treatment. (G) Transmission electron microscopy analysis showing ultrastructure of differentiated hiPSC-LO. (a) Tight
junction (black arrowhead), (b) Microvilli (blue arrowhead), (c) Lipid droplets (black arrow), and (d) Bile canaliculi (dotted line). *p b .05, **p b .01, ***p b .001; ns, not signiﬁcant.
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CYP (cytochrome P450) 3A4 activity than hiPSC-HLCs, and the CYP3A4
activity of hiPSC-LOs could be further induced by rifampicin (Fig. 1F).
We further explored the ultrastructure of the differentiated hiPSC-LO
with transmission electron microscopy (TEM). TEM data revealed that
hepatic lineages in organoids had typical hepatic features, such astight junctions, microvilli on the cell membrane, lipid droplets in the cy-
toplasm, and bile capillaries between hepatic cells (Fig. 1G). These dif-
ferentiated organoids also had the ability to uptake and release
indocyanine green (ICG) (Fig. S1F), a general characteristic of the liver.
Collectively, these results demonstrate the successful generation of a
well-differentiated hiPSC-LO with enhanced hepatic function and
118 Y.-Z. Nie et al. / EBioMedicine 35 (2018) 114–123liver-speciﬁc features by recapitulating multiple cellular interactions in
an ex vivo culture system.
3.2. Susceptibility to HBV infection in hiPSC liver organoids
To evaluate whether the differentiated hiPSC-LO could be used as a
potential hepatic source for HBV infection, we detected the expression
of NTCP in hiPSC-LOusing the q-PCR assay. Analysis showed that the ex-
pression of NTCP could be detected and was comparatively higher in
hiPSC-LOs, than in the PHHs (Fig. 2A). Immunoﬂuorescence analysisFig. 2. Susceptibility of hiPSC-derived liver organoids toHBV infection. (A)Q-PCR analysis ofNTC
HepG2 cells (n= 4), PHH-1, and PHH-2. (B) Immunoﬂuorescence analysis of ALB and NTC
representation of HBV life cycle in infected hepatocyte. (D-G) Q-PCR quantiﬁcation of HBV
circular DNA (cccDNA) (F), and supernatant vDNA (G) in HepG2-TET-NTCP (+DOX) (n= 4)
post infection (dpi) with 500 genome equivalent (GEq)/cell infection, pgRNA expression in in
vDNA in hiPSC-LOs and hiPSC-HLCs at 4, 7 and 10 dpi (n= 4). (F) The expression of GPC5, P
hiPSC-HLCs were used as a control. *p b .05, **p b .01, ***p b .001; ns, not signiﬁcant.also conﬁrmed NTCP positive hepatic lineages in the hiPSC-LO
(Fig. 2B). We then tested the infection susceptibility of hiPSC-LO with
HBV produced from HepG2.2.15.7 cells, and compared its susceptibility
with hiPSC-HLCs and PHHs through the expression of pregenomic (pg)
RNA, intercellular viral DNA (vDNA), covalently closed circular DNA
(cccDNA), and supernatant vDNA at 10 days post infection (dpi)
(Fig. 2C). In agreement with previous reports [12–14], hiPSC-HLCs
could be infected by HBV with the detection of viral RNA and DNA
(Fig. 2D-G). Further, infected hiPSC-LOs showed much higher expres-
sion of pg RNA, and increased copy numbers of intercellular vDNA,P expression inhiPSCs, hiPSC-HLCs (HLCs) (n=4), differentiatedhiPSC-LOs (LOs) (n=4),
P in differentiated hiPSC-LOs. Green, ALB; Red, NTCP. Scale bars, 50 μm. (C) Schematic
pregenomic RNA (pgRNA) (D), intracellular virus DNA (vDNA) (E), covalently closed
, hiPSC-HLCs (n= 8), hiPSC-LOs (n= 8), PHH-1(n= 4), and PHH-2 (n=4) at 10 days
fected HepG2-TET-NTCP (+DOX) as a control. (H) Q-PCR quantiﬁcation of supernatant
PARA, and CEBPA in hiPSC-HLCs (n= 4) and hiPSC-LOs (n= 4) was detected by Q-PCR,
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and Fig. S3A). Moreover, the expression levels of pg RNA and the copy
numbers of intercellular vDNA, cccDNA, and supernatant vDNA of in-
fected hiPSC-LOs were intermediate between that of two different in-
fected PHHs (Fig. 2D-G), indicating that the virus susceptibility of
hiPSC-LOwas comparable to PHHs.Wemonitored thedynamic virus re-
lease in infected hiPSC-LOs during the infection. From 7 dpi to 10 dpi, a
signiﬁcant release of viruses from the infected hiPSC-LOs was observed,
but not from infected hiPSC-HLCs (Fig. 2H). Additionally, the expression
of known infection promoting factors, GPC5 (glypican 5), PPARA (perox-
isome proliferator-activated receptor alpha), and CEBPA (CCAAT/
enhancer-binding protein alpha) [25–27], was found to be higher in
hiPSC-LO than in hiPSC-HLC (Fig. 2I). These results indicated that differ-
entiated hiPSC-LO could be a robust infection model.
3.3. Long term maintenance of hepatic function and virus propagation in
hiPSC liver organoids
Next, we evaluated the ability of differentiated hiPSC-LO tomaintain
its hepatic function and its potential to be a long-term infection model.
Dynamic monitoring showed that ALB secretion steadily increased in
differentiated hiPSC-LO, and could be sustained for 20 days (Fig. 3A).
In contrast, a sharp decline of ALB secretion was observed in hiPSC-
HLCs after only 5 days of extended culture (Fig. 3A). The expression of
CYP3A4 in hiPSC-LO also constantly increased during this period
(Fig. 3B). These results demonstrate that the hiPSC-LOs displayed
prolonged maintenance of hepatic functions, and have the potential to
be a long-term infection model.
We further investigated viral replication and propagation in hiPSC-
LOs by increasing the infection time from 10 days to 20 days. Compared
with 10 dpi infected LOs, pgRNA expression and supernatant vDNA
copy numbers markedly increased in 20 dpi infected LOs (Fig. 3C).
Such an increase was not observed in infected hiPSC-HLCs and PHHs
(Fig. 3C). Immunoﬂuorescence analysis also showed that the proportion
of HBV core antigen (HBc) positive hepatic lineages (HBc+ALB+) in-
creased in hiPSC-LOs prolonging the infection time (Fig. 3D). To further
investigate whether infectious progeny viruses could be produced from
infected hiPSC-LOs, we collected the supernatant from infected hiPSC-
LOs at 20 dpi (20 dpi-Sup, from day 17 to day 20) and examined its in-
fectivity in PXB-HHs. Notably, the progeny virus displayed infectivity,
conﬁrmed by pgRNA quantiﬁcation in PXB-HHs (Fig. 3E). Furthermore,
the progeny virus could complete their life cycle based on detectable
vDNA in the supernatant (Fig. 3E) and intracellular HBc staining
(Fig. 3F). These results indicate that this organoid system could serve
as a long-term ex vivo infection model.
3.4. Induction of hepatic dysfunction in hiPSC liver organoids with HBV
infection
The prolonged maintenance of hepatic function in differentiated
hiPSC-LOs could be helpful in understanding the host consequences
caused by virus infection without any concerns about inherent reduc-
tion in hepatic function. To explore the host consequences of viral infec-
tion,we infected thedifferentiated hiPSC-LOswith different doses of the
virus: 0 GEq (genome equivalent)/cell (non-HBV), 500 GEq/cell (low
dose), and 5000 GEq/cell (high dose) [28, 29], and analyzed the changes
in infected hiPSC-LOs. The increased amount of virus could markedly
promote the infection in hiPSC-LOs (Fig. 4A, B and S4A). Further, expres-
sion analysis established that virus infection could dose-dependently
impair the expression of CYP3A4, CYP3A7, and CYP2C9 (Fig. 4C). Addi-
tionally, a high-dose infection could down-regulate the expression of
ALB, G6PC (glucose-6-phosphatase catalytic-subunit), HNF4A (hepato-
cyte nuclear factor 4 alpha), and RBP4 (retinol binding protein
4) (Fig. 4C). To conﬁrm that the impaired expression of hepatic genes
was a result of virus infection, we used myrcludex (a HBV entry inhibi-
tor) and entecavir (an anti-HBV nucleos(t)ide) to inhibit virus infection.Upon treatment with these drugs, the expression of pg RNA, and copy
number of intracellular vDNA and supernatant vDNAwere signiﬁcantly
reduced (Fig. S4B), and the expression of hepatic functional genes was
enhanced in infected LOs (Fig. S4C). The infection impaired hepatic
gene expression was also detected in infected PHHs (Fig. 4D), but not
in infected HepG2-TET-NTCP organoids (Fig. S4E). Moreover, a de-
creased ALB secretion was observed in high-dose infected LOs
(Fig. 4E). To further conﬁrm that viruses caused hepatic dysfunction,
we measured the level of aminotransferase (ALT) and lactate dehydro-
genase (LDH) that act as markers for early acute liver failure [30], in the
supernatant of infected LOs, and found an increased level of ALT and
LDH (Fig. 4F and G). TEM analysis indicated that, compared with non-
infected LOs, the infected LOs had increased number of vacuoles in the
hepatocyte cytoplasm (Fig. 4H),which occupied a signiﬁcant proportion
of the cytoplasm and pushed the nucleus into the cell periphery
(Fig. 4H). Additionally, infected LOs showed reduced membranemicro-
villi (Fig. 4H and I), a characteristic of ﬁbrosing liver disease [31]. HBV
infection has been considered as a driving force for epithelial-
mesenchymal transition (EMT) in liver cancer development [32]. In in-
fected LOs,we found the expression of EMTmarkers SNAI2 (Snail Family
Transcriptional Repressor 2) and TWIST1 (Twist Family BHLH Transcrip-
tion Factor 1) was signiﬁcantly up-regulated (Fig. S4F). These ﬁndings
indicate that this organoid infection system could recapitulate virus in-
duced hepatic dysfunction.
During virus infection, the host innate immune cells recruited into
the infection site produce interferons (IFNs) that help inhibit and elim-
inate the virus [33]. Tomimic this immune defense, we treated infected
hiPSC-LOs with IFNα, and found that IFNα could induce transcription of
antiviral genes, including VIPERIN (virus inhibitory protein, endoplas-
mic reticulum-associated, interferon-inducible), ISG15 (interferon stim-
ulated gene 15), ISG20 (interferon stimulated gene 20), and MX2
(Myxovirus Resistance Protein 2) (Fig. S5A). Upon IFNα and IFNγ treat-
ment, virus replication was signiﬁcantly suppressed with down-
regulated expression of pgRNA (Fig. S5B), and amarked inhibition in ex-
pression of hepatic genes in the infected hiPSC-LOs (Fig. S5E). These ob-
servations suggest that the innate immune activation could effectively
inhibit virus replication but would induce additional hepatic injury in
hiPSC-LOs.
4. Discussion
In the current study,we developed a novelmethod to generate func-
tional liver organoids with a 3D microwell system (Table S2). In this
new culture system, liver organoids with small diameters (approxi-
mately 200 μm) were generated, with improved nutrient permeation
and absorption, resulting in effective hepatic differentiation and suscep-
tibility to HBV infection. The susceptibility of hiPSC-LOs to infectionwas
comparable to cryopreserved PHHs.Moreover, this organoid system can
mimic the virus induced hepatic dysfunction, indicating that infection in
hiPSC-LOs might be able to recapitulate in vivo virus - host interactions.
With exogenous expression of humanNTCP, different donor derived
humanhepatocarcinoma cells could gain susceptibility toHBV infection,
but their susceptibility varied among cells [34]. Meanwhile, mouse he-
patocytes overexpressing human NTCP were not susceptible to HBV in-
fection [35]. These studies have conﬁrmed that NTCP is a necessary
factor but not sufﬁcient for HBV infection; other human liver speciﬁc
factors would also be necessary in the regulation of HBV life cycle, and
these factors may be related to the host's genetic background. To test
this idea, we compared the HBV infection in LOs generated from differ-
ent genetic background and observed different levels of susceptibility
among them (Fig. S3B). Furthermore, we found that hiPSC-LOs and
hiPSC-HLCs generated from same genetic background had comparable
expression of NTCP, but had signiﬁcant difference in virus susceptibility,
suggesting that hepatic lineages in distinct differentiation stages might
express different levels of liver-speciﬁc factors important for virus infec-
tion. Thus, further detailed analysis of the differences between single
Fig. 3. Long-term maintenance of hepatic function and HBV propagation in hiPSC liver organoids. (A) ELISA for ALB secretion of hiPSC-HLCs and differentiated hiPSC-LOs in extended
culture (n= 5, each). (B) Q-PCR analysis of CYP3A4 expression of hiPSC-LOs during extended culture, n=3. (C) Quantiﬁcation of HBV pgRNA (left) and supernatant vDNA (right) in
hiPSC-HLCs (n=4), hiPSC-LOs (n=8), PHH-1 (n=4) and PHH-2 (n=4) at 10 and 20 dpi by Q-PCR. 10 dpi of hiPSC-HLCs was used as a control. (D) Immunoﬂuorescence analysis of
ALB and HBc in infected hiPSC-LOs at 10 and 20 dpi. Infection rates were calculated based on the number of HBc and ALB double positive cells (ALB+HBc+) relative to that of total
ALB-positive cells (ALB+), n= 24 liver organoids. (E) Quantiﬁcation of HBV pgRNA and supernatant vDNA in PXB-HH infected with supernatant of infected hiPSC-LOs (20 dpi) and
HBV derived from HepG2 2.15.7 (n = 6 each) at 10 dpi, non-infected PXB-HH was used as a negative control (F) Immunoﬂuorescence analysis of HBc in PXB-HH infected with
supernatant of infected hiPSC-LOs (20 dpi) and HBV derived from HepG2 2.15.7 at 10 dpi. *p b .05, **p b .01, ***p b .001, ns, not signiﬁcant.
120 Y.-Z. Nie et al. / EBioMedicine 35 (2018) 114–123donor-derived LO and HLC would help in the identiﬁcation of po-
tential risk and resistance factors for infection. Our novel functional
hiPSC-LO provides a new avenue to investigate the role of the hostgenetic background in HBV infection and prognosis of individual in-
fection and has the potential to be used in personalized hepatitis
treatment.
Fig. 4. Induction of hepatic dysfunction in hiPSC liver organoids with HBV infection. (A) Immunoﬂuorescence analysis of HBc and ALB in hiPSC-LOs at doses of 0 (Non-HBV), 500 (low
dose), and 5000 (high dose) GEq/cell infection at 10 dpi. (B) The percentage of ALB+HBc+ cells relative to that of total ALB+ cells, n=22 liver organoids. (C) Q-PCR quantiﬁcation of
hepatic genes ALB, HNF4A, G6PC, RBP4, CYP3A4, CYP3A7, and CYP2C9 in non-, low-dose and high-dose HBV-infected hiPSC-LOs at 10 dpi, n= 4. (D) Q-PCR quantiﬁcation of hepatic
genes ALB, HNF4A, G6PC, RBP4, CYP3A4, CYP3A7, and CYP2C9 in non-, low-dose and high-dose HBV-infected PHH-2 at 10 dpi, n= 3. (E) ELISA analysis of ALB secretion in non- and
high-dose HBV-infected hiPSC-LOs, n= 5. (F) Quantiﬁcation of ALT in the supernatant of non- and high-dose HBV-infected hiPSC-LOs at 10 dpi, n= 5. (G) Detection of LDH in the
supernatant of non- and high-dose HBV-infected hiPSC-LOs at 10 dpi, n=5, non-HBV group used as a control. (H) Transmission electron microscopy analysis of the ultrastructure of
hiPSC-LOs with non- and high-dose HBV infection at 10 dpi, N: nuclear; V: vacuole; L: lipid drop; blue arrow: microvilli. (I) Numbers of microvilli in non- and high-dose HBV infected
hiPSC-LOs, n=5.
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lieved that the virus itself might not cause the hepatocellular damage
in acute and chronic HBV infection [36]; some studies have also stated
that HBV infection could not induce hepatic apoptosis [37, 38]. How-
ever, thesemodels likely display cancer cell characteristics and unstablehepatic function, due to which they probably could not reproduce nor-
mal viral cytopathic effects. Besides, subsequent studies have observed
that HBV infection could induce hepatic damage in patients and
mouse models with severe immunosuppression [39, 40], suggesting
that HBV may indeed cause cytopathic effects on hepatocytes in vivo,
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study, we accidentally found that HBV could induce hepatic dysfunction
of hiPSC-LOs with signiﬁcantly reduced hepatic function, induced re-
lease of hepatic injurymarkers, and altered hepatic ultrastructure. Func-
tional LOs generatedwithout immune cells,when infected, displayed an
impaired hepatic function, further favoring the idea that HBVmight be a
cytopathic virus. Although the mechanisms underlying the cytopathic
effects of the virus have not yet been deﬁned, the accumulation of
HBV proteins has been reported to result in the appearance of cellular
vacuolization in hepatocytes [39], and to induce stress and increase re-
active oxygen species (ROS) in the endoplasmic reticulum [41]. The in-
creased ROS might further induce autophagy and disrupt membrane
lipids to alter hepatic ultrastructure [42, 43]. In this study, we found
that HBV infection did not induce cell apoptosis or lysis of hiPSC-LOs
(Fig. S4D), supporting the view that HBV might be a cytopathic virus,
but not a cytolytic one.
The highly efﬁcient and fast hepatic innate immune response to
pathogen is initiated through IFNs [44]. Inhibition of IFN activation
could induce robust replication of HBV in PHHs [13], but this HBV-
activated IFN response in hepatocytes was not detected in hiPSC-LOs
(Fig. S5F) or in other infected hepatic cells [45]. This loss of self-
defense might advance the stealthy replication of HBV in hiPSC-LOs.
Although studies have suggested that IFNs inhibit HBV replication in
a non-cytolytic manner [46, 47], our results suggest that IFNs could ef-
ﬁciently inhibit viral replication, but could also inhibit hepatic function
in the infected hiPSCs-LOs. This aggravated hepatic injury might be a
side effect of IFNs. This IFN-mediated liver injury has also been ob-
served in mice models and clinical trials [48, 49]. We were unable to
observe IFN induced cccDNA degradation in infected LOs, possibly be-
cause of the low APOBEC3A expression in hiPSC-LOs (Fig. S5C and
S5D) [47]. These observations suggest that the organoids may still
have some characteristics different from adult hepatocytes. Thus, fur-
ther efforts are required to generate adult liver-like organoids from
hiPSCs.
In summary, we have generated functional hiPSC-LOs that can efﬁ-
ciently recapitulate host-virus interactions by mimicking the virus life
cycle and display HBV-induced hepatic dysfunction, indicating that
this LO may be a reliable and feasible personalized infection model for
individualized hepatitis study and treatments.
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